SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS)

Q: What does CUSIP 78397T202 represent in this 13F holders report?

CUSIP 78397T202 is the security identifier for SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share used to aggregate holder disclosures.

Q: How many institutions held SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share in Q3 2024?

24 institutional investors reported SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share for Q3 2024. Use the holders table for investor-level position and value details.

CUSIP: 78397T202

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class: Equity / Common Stock, $0.0001 par value per share
Shares outstanding: 76,568,369
Total 13F shares: 3,141,736
Share change: +25,373
Total reported value: $8,482,377
Price per share: $2.70
Number of holders: 24
Value change: +$68,507
Number of buys: 6
Number of sells: 5

Quarterly Holders Quick Answers

What is CUSIP 78397T202?
CUSIP 78397T202 identifies SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q4 2024
Previous quarter: Q2 2024

Recent filing periods for CUSIP 78397T202:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of SABS - SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Edward D. Hamilton	3/4/5	10%+ Owner	— mixed-class rows	9,456,382 mixed-class rows	$9,348,396	—	22 Oct 2021	3/4/5
BVF INC/IL	13F	Company	1.2%	917,826	$2,845,261	—	30 Jun 2024	13F
Ilan Katz	3/4/5	Director, 10%+ Owner	— class O/S missing	3,049,325	$2,683,406	—	13 Oct 2021	3/4/5
RTW INVESTMENTS, LP	13F	Company	1%	766,946	$2,377,533	—	30 Jun 2024	13F
MARSHALL WACE, LLP	13F	Company	0.6%	459,168	$1,423,421	—	30 Jun 2024	13F
Sessa Capital IM, L.P.	13F	Company	0.6%	458,457	$1,421,217	—	30 Jun 2024	13F
VANGUARD GROUP INC	13F	Company	0.36%	276,336	$856,641	—	30 Jun 2024	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.08%	59,415	$184,222	—	30 Jun 2024	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.07%	52,784	$163,630	—	30 Jun 2024	13F
Pathstone Holdings, LLC	13F	Company	0.07%	50,650	$157,016	—	30 Jun 2024	13F
FIRST MANHATTAN CO. LLC.	13F	Company	0.03%	24,577	$76,189	—	30 Jun 2024	13F
First PREMIER Bank	13F	Company	0.03%	19,386	$60,000	—	30 Jun 2024	13F
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC	13F	Company	0.03%	19,201	$59,523	—	30 Jun 2024	13F
BlackRock Finance, Inc.	13F	Company	0.02%	13,752	$42,631	—	30 Jun 2024	13F
LMR Partners LLP	13F	Company	— class O/S missing	539,588	$25,576	—	30 Jun 2024	13F
OSAIC HOLDINGS, INC.	13F	Company	0.01%	4,534	$14,055	—	30 Jun 2024	13F
Shaolin Capital Management LLC	13F	Company	— class O/S missing	249,143	$11,809	—	30 Jun 2024	13F
MORGAN STANLEY	13F	Company	— mixed-class rows	147,138 mixed-class rows	$9,108	—	30 Jun 2024	13F
Tower Research Capital LLC (TRC)	13F	Company	— mixed-class rows	2,441 mixed-class rows	$7,420	—	30 Jun 2024	13F
Yakira Capital Management, Inc.	13F	Company	— class O/S missing	108,485	$5,142	—	30 Jun 2024	13F
Michael G. King Jr.	3/4/5	CHIEF FINANCIAL OFFICER	— mixed-class rows	120,000 mixed-class rows	$4,400	—	21 Feb 2024	3/4/5
Princeton Global Asset Management LLC	13F	Company	0%	500	$1,550	—	30 Jun 2024	13F
Walleye Capital LLC	13F	Company	— class O/S missing	23,258	$1,102	—	30 Jun 2024	13F
Walleye Trading LLC	13F	Company	— class O/S missing	15,505	$735	—	30 Jun 2024	13F
WOLVERINE ASSET MANAGEMENT LLC	13F	Company	— class O/S missing	15,319	$726	—	30 Jun 2024	13F
GS Investments, Inc.	13F	Company	0%	200	$620	—	30 Jun 2024	13F
BANK OF AMERICA CORP /DE/	13F	Company	— mixed-class rows	365 mixed-class rows	$520	—	30 Jun 2024	13F
JPMORGAN CHASE & CO	13F	Company	0%	106	$329	—	30 Jun 2024	13F
HARBOUR INVESTMENTS, INC.	13F	Company	0%	50	$155	—	30 Jun 2024	13F
NewEdge Advisors, LLC	13F	Company	— class O/S missing	1,072	$50	—	30 Jun 2024	13F
Qube Research & Technologies Ltd	13F	Company	0%	6	$19	—	30 Jun 2024	13F
UBS Group AG	13F	Company	— class O/S missing	56	$3	—	30 Jun 2024	13F
Russell P. Beyer	3/4/5	Chief Financial Officer	— class O/S missing	275,000	—	—	14 Mar 2023	3/4/5
Charles Hiram Randall	3/4/5	Chief Strategy Officer	— mixed-class rows	157,313 mixed-class rows	—	—	22 Oct 2021	3/4/5
Mervyn Turner	3/4/5	Director	— mixed-class rows	79,192 mixed-class rows	—	—	22 Oct 2021	3/4/5
Hua Wu	3/4/5	SVP Research & Product Dev.	— mixed-class rows	43,823 mixed-class rows	—	—	22 Oct 2021	3/4/5
Frederick Finnegan	3/4/5	Chief Business Officer	— class O/S missing	23,453	—	—	16 Mar 2022	3/4/5
Thomas Charles Luke	3/4/5	Chief Medical Officer	— class O/S missing	20,519	—	—	16 Mar 2022	3/4/5
Jeffrey G. Spragens	3/4/5	Director	— class O/S missing	20,000	—	—	15 Jul 2024	3/4/5
Bruce Kipp Erickson	3/4/5	Chief Operating Officer	— class O/S missing	18,196	—	—	16 Mar 2022	3/4/5
Carlos N. Carillo	3/4/5	SVP Regulatory Affairs	— class O/S missing	17,681	—	—	22 Oct 2021	3/4/5
Melissa Vera Ullerich	3/4/5	Chief Communications Officer	— class O/S missing	16,405	—	—	16 Mar 2022	3/4/5
Jerry Lynn Pommer	3/4/5	Chief Compliance Officer	— class O/S missing	15,172	—	—	16 Mar 2022	3/4/5
David Charles Link	3/4/5	Director	— class O/S missing	9,305	—	—	15 Jul 2024	3/4/5
Christine Hamilton Power	3/4/5	Director	— class O/S missing	6,773	—	—	15 Jul 2024	3/4/5

Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) as of Q3 2024

As of 30 Sep 2024, SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (SABS) was held by 24 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,141,736 shares. The largest 10 holders included BVF INC/IL, RTW INVESTMENTS, LP, MARSHALL WACE, LLP, Sessa Capital IM, L.P., VANGUARD GROUP INC, HB Wealth Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, Pathstone Holdings, LLC, and FIRST MANHATTAN CO. LLC.. This page lists 25 institutional shareholders reporting positions in this security for the Q3 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q3 2024 vs Q2 2024 Across Filers

Q2 2024 holders

Q3 2024 holders

Holder diff

Investor	Q2 2024 Shares	Q3 2024 Shares	Share Diff	Share Chg %	Q2 2024 Value $	Q3 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.